What does the evidence currently show Data from randomized controlled trials (RCTs) and meta-analysis of RCTs show that semaglutide and tirzepatide (two types of GLP-1 medications) reduce body weight, waist circumference, and improve major cardiometabolic risk biomarkers (e.g
Two compounds hitting genuinely different mechanisms (as BPC-157 and TB-500 do) produce a broader research envelope than either alone
Veterinary testing: Laboratory tests are performed to make sure either therapy is showing its effects or not
Tirzepatide works best when combined with other healthful lifestyle choices, such as a nutritious diet and regular physical activity
These enzymes include ALT (alanine aminotransferase), AST (aspartate aminotransferase), ALP (alkaline phosphatase), and GGT (gamma-glutamyl transferase)
As we move through 2026, the conversation around medical weight loss has shifted from just physical transformation to a deeper look at the mind-body connection